| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total non-operating income, net | 1,892 | 2,040 | 3,655 | 3,512 |
| Net loss from continuing operations | -25,969 | -21,999 | -18,177 | -15,122 |
| Net loss before deferred income tax benefit | - | - | - | -15,122 |
| Net gain (loss) from discontinued operations | 0 | 514 | - | - |
| Net loss | -25,969 | -21,485 | -18,177 | -15,122 |
| Basic and diluted (in shares) | 74,296,000 | 74,235,000 | 72,357,000 | 70,629,000 |
| Basic loss per share | -0.35 | -0.29 | -0.25 | -0.21 |
| Diluted loss per share | -0.35 | -0.29 | -0.25 | -0.21 |
| Weighted average number of shares outstanding, diluted, total | 74,296,000 | 74,235,000 | 72,357,000 | 70,629,000 |
Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics, Inc. (CATX)